Our Programs

Pipeline

We are leveraging our deep understanding of recent biological discoveries in endocrinology to build our clinical pipeline. Our focus is on advancing the development of novel, potentially first-in-class treatments for endocrine diseases with significant unmet need. Livoletide (AZP-531) is an unacylated ghrelin analogue for treatment of Prader-Willi syndrome and nevanimibe (ATR-101) is an ACAT1 inhibitor currently being investigated in two orphan adrenal indications, classic congenital adrenal hyperplasia (CAH) and endogenous Cushing’s syndrome (CS).

Millendo Pipeline